Curcumin conjugates for treating and preventing cancers

US9937260B2 · kind B2 · utility

Assignees

• Board of Supervisors of Louisiana State University · US
• AGRICULTURAL AND MECHANICAL COLLEGE · US

Inventors

• William Hansel · Baton Rouge, US
• Sita Aggarwal · Hammond, US
• Robert P. Hammer · Baton Rouge, US

Key dates

• Filing date: Dec 21, 2015
• Grant date: Apr 10, 2018
• Expiry date: Dec 21, 2035

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Conjugating LHRH to curcumin (LHRH-Curcumin) substantially enhances the bioavailability of curcumin, targets it to cells expressing LHRH receptors, facilitates intravenous administration, and increases the anti-cancer efficacy of curcumin. The conjugate may be used against cancer cells that express the LHRH receptor: pancreas, prostate, breast, testicular, uterine, ovarian, melanoma. LH-Curcumin conjugates may be used against cancer cells that express the LH receptor: prostate, breast, ovary, testis, uterus, pancreas, and melanoma.